Rare Disease Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve patient ...
The US Food and Drug Administration (FDA) has cleared AnemoCheck Home for patients with sickle cell disease (SCD), iron deficiency anemia, vitamin B12 deficiency anemia, folate deficiency anemia, and ...
Consolidation or maintenance therapy significantly improved progression-free survival and overall survival. Zanubrutinib, lenalidomide, temozolomide, and rituximab (RLZT) combined with or without high ...
Patients who achieve a complete metabolic response to R-CHOP have a 5-year OS of about 75%, compared with 35% in those without a complete response. F-fluorodeoxyglucose positron emission ...
More than half of responders with MDS or AML remained relapse-free for at least 2 years. Measurable residual disease (MRD)-guided preemptive azacitidine effectively delayed relapse and produced ...
Persistent hypoalbuminemia with intestinal lymphangiectasia and recurrent edema should prompt consideration of CHAPLE disease and genetic confirmation. Early recognition of CD55 deficiency with timely ...
Meta-analysis estimates global PPF incidence at 10.9/100,000 and prevalence at 37/100,000, rarer in Europe and Asia but higher in the US. The pooled global incidence and prevalence of progressive ...
After switching to poze-cemdi in an open-label extension, 4 of the 5 patients who struggled with ravulizumab achieved lactate dehydrogenase control. The pozelimab and cemdisiran (poze-cemdi) ...
Real-world data confirmed the safety and efficacy of vosoritide, showing height increases of up to 11.86 cm over 24 months in children with achondroplasia. Vosoritide (Voxzogo ®) continued to ...
Taylor Kane is executive director of Remember the Girls, a nonprofit group that advocates on behalf of females with X-linked disorders (Photo courtesy of Taylor Kane) New Jersey native Taylor Kane ...
(Getty Images/manassanant pamai) Final results of a phase 3 trial of iptacopan in IgAN showed slower eGFR decline, reduced kidney failure risk, and other benefits. At month 24, UPCR reduction was ...
Dana Rizk, MD, professor of medicine in nephrology at the University of Alabama at Birmingham Heersink School of Medicine, speaks at the Renal Physicians Association 2026 Annual Meeting in Atlanta, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results